Compare Incyte Corporation (INCY) vs Taskus Inc (TASK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Taskus Inc — how do they compare? Incyte Corporation trades at $117.97 (market cap $23.11B), while Taskus Inc trades at $5.83 (market cap $532.07M). The key difference: Incyte Corporation is far larger — about 43.4× Taskus Inc's market cap, and Incyte Corporation is trading nearer its 52-week high, Taskus Inc nearer its low. Which is the better fit depends on your goals.
| INCY | TASK | |
|---|---|---|
Market Cap | $23.11B | $532.07M |
Sector | Health | Technology |
52-Week High | $118.52 | $18.21 |
52-Week Low | $67.38 | $4.57 |
Enterprise Value | $19.13B | $927.77M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
TaskUs (TASK) trades at $5.81, down 0.34% on the day, with a bullish technical signal from moving averages but bearish oscillators. The company reported Q1 2026 earnings of $0.35 per share, missing estimates, after beating in the prior two quarters. Revenue reached $1.18 billion in 2025 with net income of $102.28 million, showing strong profitability. Analysts maintain a consensus buy rating with a $9.50 price target, suggesting significant upside potential.
The stock appears undervalued with a P/E of 5.16 and P/S of 0.45, supported by robust ROE of 26.52%. Risks include recent earnings miss and competitive pressures in digital services. Positive cash flow and debt reduction trends provide fundamental strength, but investor sentiment is mixed amid technical overbought signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Taskus Inc
TaskUs Inc is a provider of outsourced digital services and next-generation customer experience to innovative and disruptive technology companies. It serves clients in the fastest-growing sectors, including social media, e-commerce, gaming, streaming media, food delivery and ridesharing, HiTech, FinTech and HealthTech.
Read more on TASK →
